Balyasny Asset Management’s 2seventy bio TSVT Stock Holding History

Balyasny Asset Management’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-394,013	Closed	-$1.95M	–	3362
2025 Q1	$1.95M	Buy	+394,013	New	+$1.25M	﹤0.01%	1709
2024 Q2	–	Sell	-38,434	Closed	-$206K	–	3123
2024 Q1	$206K	Buy	+38,434	New	+$181K	﹤0.01%	2393
2023 Q4	–	Sell	-636,787	Closed	-$2.5M	–	2914
2023 Q3	$2.5M	Buy	+636,787	New	+$4.18M	0.01%	1319
2023 Q2	–	Sell	-1,437,302	Closed	-$14.7M	–	2803
2023 Q1	$14.7M	Buy	+1,437,302	New	+$16.4M	0.04%	628
2022 Q4	–	Sell	-282,058	Closed	-$4.1M	–	3250
2022 Q3	$4.1M	Sell	282,058 -174,876	-38%	-$2.6M	0.01%	1103
2022 Q2	$6.03M	Buy	456,934 +72,115	+19%	+$983K	0.02%	857
2022 Q1	$6.57M	Buy	+384,819	New	+$6.53M	0.02%	846

Other funds holding TSVT

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Balyasny Asset Management's TSVT Position: Q2 2025 in Review

Balyasny Asset Management sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 394,013 shares — an estimated $1.95M sold.

Balyasny Asset Management first reported a position in TSVT in Q1 2022 and held it in 7 quarters. The position peaked at $14.7M in Q1 2023. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

Balyasny Asset Management reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
Balyasny Asset Management sold 394,013 2seventy bio shares in Q2 2025, an estimated $1.95M.
Balyasny Asset Management first reported a position in 2seventy bio in Q1 2022 and held it in 7 quarters.
Balyasny Asset Management's 2seventy bio position peaked at $14.7M in Q1 2023.
2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Balyasny Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.